Shionogi Boosts FY2026 Outlook With Strong First‑Half Results and Robust Pipeline
Shionogi lifts FY2026 outlook after strong first‑half, driven by antibiotic sales and a growing pipeline, boosting revenue, EPS and dividend prospects.
4 minutes to read
